fuzzyjr

Some food for thought to pass the time until a deal is announced: 

The 6/22/20 news release indicating FDA agreement for key aspects of the apabetalone registration enabling study put RVX-208 in the spotlight for a partnership with BP. 

" In total, approximately 25% of BETonMACE patients were on new oral anti-diabetic treatments that included SGLT2 and DPP4 inhibitors. In combination with apabetalone, primary MACE was reduced by 57% and by 63% when hospitalization for congestive heart failure was included. We believe the efficacy and safety demonstrated with this combination approach will greatly assist in our strategic partnership discussions and significantly improves our intellectual property and commercial runway position. In short, we can demonstrate efficacy, safety and we believe we now have a clear path to commercialization."

Also, a Chinese connection may be good -

"Building upon previous predictions from 2019, we also expect to see China continuing their growth as a key player within the pharmaceutical industry in the coming decade, partially driven by reformed priority review and approval process that allows domestic drug developers to compete with multinational counterparts. With these changes we expect a more levelled global playing field in the world of biopharma deals, with an increase in both frequency and size of deals that involve Chinese companies."

 https://mscnordics.com/largest-biotech-and-pharma-deals-2019-recap-2020-outlook/

Table 2. Top 10 partnership deals (Pharma and biotech)

My bet is that a US BP with an anti-diabetic therapy on the market partners with Resverlogix in a deal similar to those listed above to improve their therapy, save lives, and protect and prolong their revenue stream.

jmo

Chicagoest